Please assess the completion status of the following clinical trial:

Trial Title: Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years old or elder.~2. HCV and HIV co-infected patients.~3. Patients with antiretroviral treatment based in NVP plus 2 NRTIs (or 1 NRTI and Tenofovir), with undetectable viral load (under 50 copies/mL) during at least the last 24 weeks.~4. If women and of childbearing age, negative pregnancy test. Furthermore, barrier contraceptive method must be undertaken during the study.~5. Date and signature of the informed consent.~Exclusion Criteria:~1. Concomitant treatment with drugs that can significantly interact with the study drugs.~2. Opportunistic infections in the last 6 months.~3. Patients who can be candidates for an HCV infection treatment in the next 3 years.~4. Patients in who efficacy of previous NRTIs can not be ensured. For example, patients with mono or dual therapy history or with previous blips in whom NRTI-related mutations were identified that could reduce the sensibility to the used backbone.~5. Active alcohol consumption (over 50 g per day) or other substance abuse.~6. Pregnant or breastfeeding women.~7. Patients with transaminase level over 5 times the Upper Limit of Normality (ULN) or Creatinin over 2 mg/dL or Total Bilirubin over 3 times the ULN.~8. Any formal contraindication for being treated with the study drugs.~9. Patients who, basing in their antiretroviral treatment history, could be considered as being infected with a virus that has no sensibility to LPV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Nevirapine
- 2 (Type: EXPERIMENTAL): Lopinavir/ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).